1H-4(5)-substituted imidazole derivatives
US6448282B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2000 |
| Grant date | Sep 10, 2002 |
| Priority date | — |
| Expiry date | Aug 2, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/64
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, in its principal aspect, compounds of the general formula: whereA is —NHCO—, —N(CH3)—CO—, —NHCH2—, —N(CH3)—CH2—, —COCH2—, —CH2CH2—, or —CH(OH)CH2—,X is H, CH3, NH2, NH(CH3), N(CH3)2, OCH3, or SH;R2 is hydrogen or a methyl or ethyl group;R3 is hydrogen or a methyl or ehtyl group;n is 0, 1, 2, 3, 4, 5 or 6;R1 is selected from the group consisting of (a) alkyl; (b) C3 to C8 cycloalkyl; (c) phenyl or substituted phenyl; (d) heterocyclic; (e) decahydronaphthalene and (f) octahydroindane; or R1 and X may be taken together to denote a 5,6 or 6,6 saturated bicycle ring structure.The compounds of the present invention have H3 histamine receptor antagonist activity. This invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of formula 1.0. The present invention also provides a method of treating conditions in which antagonism of histamine H3 receptors may of therapeutic importance.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.